|
Volumn 38, Issue 15, 2002, Pages 1984-1986
|
The ATAC (Arimidex™, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: Factors influencing the success of patient recruitment
|
Author keywords
Anastrozole; Aromatase inhibitor; Early breast cancer; Trial recruitment
|
Indexed keywords
ANASTROZOLE;
TAMOXIFEN;
ANTINEOPLASTIC AGENT;
NITRILE;
TRIAZOLE DERIVATIVE;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG SCREENING;
HUMAN;
MEDICAL PRACTICE;
METHODOLOGY;
PATIENT INFORMATION;
POSTMENOPAUSE;
PRIORITY JOURNAL;
STANDARDIZATION;
ADJUVANT CHEMOTHERAPY;
BREAST TUMOR;
DOUBLE BLIND PROCEDURE;
FEMALE;
PATIENT SELECTION;
QUESTIONNAIRE;
RANDOMIZED CONTROLLED TRIAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
NITRILES;
PATIENT SELECTION;
POSTMENOPAUSE;
QUESTIONNAIRES;
TAMOXIFEN;
TRIAZOLES;
|
EID: 0036771649
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/S0959-8049(02)00154-5 Document Type: Article |
Times cited : (26)
|
References (6)
|